PUBLIC COMPANY
save$NMRANeumora Therapeutics, Inc.
$NMRAWatertown, MA, USupdated 2mo ago
community read0 votes
pipeline
1
marketed
0
phase 3
1
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 3
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase3Study to Assess the Safety and Effectiveness of NMRA-335140-501
- phase3Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder
- phase3Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder
- phase2To Evaluate the Effects of NMRA-335140 on Symptoms of Major Depression in Participants With Bipolar II Disorder.
- phase3Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder
- phase1Study to Evaluate the Effects of NMRA-323511 Among Healthy Elderly and Adults With Agitation Associated With Dementia Due to Alzheimer's Disease
- phase2Study in Major Depressive Disorder With NMRA-335140 (BTRX-335140) vs Placebo
Insider activity
source: SEC Form 4🐶 Hiring Signal
Where Neumora Therapeutics, Inc. is staffing up — a leading indicator of pipeline and commercial priorities.
departmentMedical Affairs 1
News
- Novo’s late-stage IL-6 stumble shakes inflammation spaceNovo Nordisk was banking on the inflammatory benefits of its investigational therapy ziltivekimab to improve cardiovascular outcomes. Last week’s Phase 3 failure dashed not just the Danish pharma’s…biospace · 11d ago
Data sources
last refreshed 12m ago
Found something off?
comments(0)
5-min edit window · permanent after that